A MaxCyte® Enabled Mammalian Display Method For The Development Of Enhanced Affinity TCR-Based Biologics

Enhanced T-cell receptor (TCR)-based therapeutics are emerging as a promising alternative to traditional cancer treatments. One key challenge in developing these therapies is ensuring high antigen affinity and favorable biophysical properties when TCR sequences are expressed in mammalian cell lines.

Mammalian display offers a solution by enabling the selection of high-affinity sequences within the relevant therapeutic context, potentially reducing immunogenicity and avoiding the need for reformatting that could compromise affinity or function. This method involves creating and screening libraries of mammalian cells displaying candidate proteins to identify those with enhanced antigen binding. Efficient and scalable transfection technologies, such as flow electroporation, are critical for generating comprehensive mammalian display libraries.

Discover how mammalian display can accelerate the development of TCR-based biologics for cancer immunotherapy.